Ameliorative Effect of Beraprost Sodium on Celecoxib Induced Cardiotoxicity in Rats

Shafique Ahmad\textsuperscript{a}, Bibhu Prasad Panda\textsuperscript{a}, Mohammad Fahim\textsuperscript{b}, Neha Dhyan\textsuperscript{c} and Kiran Dubey\textsuperscript{a}

\textsuperscript{a}Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India. \textsuperscript{b}Department of Anatomy and Physiology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, India. \textsuperscript{c}Department of Life Sciences, Indira Gandhi National Open University, New Delhi, India.

Abstract

Selective COX-2 inhibitors are most widely used analgesic and anti-inflammatory drugs; however, its maximal use is highly associated with various serious abnormal cardiovascular events. Beraprost sodium (BPS), prostacyclin analogue has been shown to vasodilatory, antiplatelets, anti-inflammatory, and antioxidant activity. The objective of the present study was to evaluate the effect of BPS on celecoxib cardiotoxicity in rats. Toxicity was induced in male Albino rats (250-280 g) by celecoxib (100 mg/kg/day). BPS (30 μg/kg/day) was administered alone and in combination with celecoxib for 14 days and various biochemicals, hemodynamic, left ventricular, biochemical, and histopathological parameters were studied. Cardiotoxicity of celecoxib was revealed by a significant increase in serum lactate dehydrogenase (LDH), troponin-T (Tn-T), tumor necrosis factor-α (TNF-α), creatine kinase-MB (CK-MB) and systolic blood pressure (SBP), left ventricular end diastolic pressure (LVEDP), LV (dp/dt)\textsubscript{max}, and LV (dp/dt)\textsubscript{min}, as well as tissue thiobarbituric acid reactive substance (TBARS) and a significant decrease in tissue reduced glutathione (GSH). However, treatment with BPS reversed these alteration in LDH, Tn-T, TNF-α, CK-MB, SBP, LVEDP, LV (dp/dt)\textsubscript{max}, LV (dp/dt)\textsubscript{min}, TBARS and GSH levels. The histopathological study in cardiac left ventricle revealed protection of myocardium as manifested reduction of fibrosis by abolition of collagen deposition when celecoxib was combined with beraprost sodium. It could be concluded that beraprost sodium may prove a useful adjunct in patients being prescribed celecoxib.

Keywords: Beraprost Sodium; Cardiotoxicity; Celecoxib; Troponin-T; Tumor necrosis factor-α.

Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are most widely used therapeutic agents for the management of short and long term pain as well as in various inflammatory conditions. Unfortunately, its long term usage shows wide array of side effects including increased risk of cardiovascular complications (1). Inhibition of cyclo-oxygenase pathway plays an important role in the pain relieving mechanism as well as also in conversion of arachidonic acid into thromboxanes and prostaglandins (2). The coxibs (celecoxib) are potent cyclooxygenase-2 (COX-2) inhibitors that fall under the class of NSAIDs (3). Imbalance between the thromboxane A\textsubscript{2} (TXA\textsubscript{2}) and prostacyclin...
(PGI₂) levels is due to coxibs responsible for the thrombosis, atherosclerosis, and other cardiovascular abnormality (4). Evidences from the systematic review and meta-analysis suggested that use of celecoxib is associated with increased risk of myocardial infarction (5). Solomon et al. (6) in his randomized controlled study reported that long term use of celecoxib is linked with risk factor for the cardiovascular causes, heart failure, myocardial infarction, and stroke. Previously, it has been also claimed that effects on PGI₂, and renal function due to selective COX-2 inhibitor with celecoxib administration might be associated with the abnormal blood pressure (7). Also, finding of Zaitone et al. (8) indicated that celecoxib could be responsible for the altered blood pressure which is an important hallmark of cardiovascular risk.

Beraprost sodium (BPS) is a synthetic PGI₂ receptor agonist and mimics similar to pharmacological profile as prostacyclin (9) such as vasodilatory effects (10), antiplatelet effects (11), anti-thrombotic (12), inhibition of vascular smooth muscle cells proliferation, and inflammatory cytokines production (13). Studies showed that beraprost sodium reduced the oxidative stress and inflammatory injury in diabetic cardiomyopathy model through p38 MAPK signalling pathway in high fat diet induced rats (14). BPS with its PGI₂ receptor agonist potency inhibits TNF-α expression in lipopolysaccharide induced lung alveolar epithelial cells injury (15). In addition, Lefer et al. (16) reported that prostacyclin have cardio-protective effect during acute myocardial ischemia and reperfusion in-vivo and in-vitro animal paradigm.

However, effect of BPS and celecoxib against cardiovascular abnormalities has not been yet properly evaluated. Hence, the aim of present investigation was to evaluate the efficacy of BPS against celecoxib induced cardiovascular toxicity by assessing various indices such as hemodynamic, left ventricular function, Biochemical, and histological changes in experimental rats.

Experimental

Drugs and Chemicals

Beraprost sodium was purchased from Sigma Aldrich, USA and Cayman Chemical, USA respectively. Celecoxib was procured as gift samples from Aurobindo Pharma Ltd. India. lactate-dehydrogenase (LDH) kit and creatine kinase (CK-MB) kit was purchased from Reckon Diagnostics Pvt. Ltd. ELISA Kits for estimations of Troponin-T (Tn-T) and Tumour necrosis factor-alpha (TNF-α) were obtained from Kinesis DX Ltd., USA and Krishgen biosystem Ltd., India respectively. All other chemicals used in the experiment were of analytical grade.

Animals

Adult male albino Wistar rats (250 to 280 g) were procured from the Central Animal House Facility, Hamdard University, New Delhi, India. The animals were kept in polypropylene cages under standard laboratory conditions (12-h night/dark cycles) and had free access to a commercial pellet diet and water ad libitum. The animal house temperature was maintained at 25 ± 2 °C. The protocol was approved by the Institutional Animal Ethics Committee and all studies were conducted under the guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India on animal experimentation (Protocol No-688/2010).

Groups of animal

The rats were divided into following groups (n = 8):

Group I: Control 0.5 mL/kg 1% CMC p.o. for 14 days.

Group-II: Celecoxib (CEL) per se 100 mg/kg p.o. in 1% CMC for 14 days.

Group-III: Beraprost sodium (BPS) per se 30 μg/kg p.o. for 14 days.

Group-VI: CEL + BPS: Celecoxib 100 mg/kg p.o + Beraprost sodium 30 μg/kg p.o. for 14 days.

Dose selection of celecoxib (100 mg/kg, p.o.) and beraprost sodium (30μg/kg, p.o) was based on the previous study (17, 18). After hemodynamic and left ventricular function measurement, the blood was withdrawn by cardiac puncture and the animals were sacrificed by cervical dislocation. The heart was rapidly removed and the separated serum from blood
was stored at -80 °C for the assessment of various biochemical parameters. A heart of a rat in each group was removed and fixed in 10% formalin solution for the histopathology (Masson’s trichrome staining).

**Hemodynamic and Left Ventricular Function Measurements**

At the end of treatment period, the animals were weighed and anaesthetized with urethane (1 g/kg, IP) Hemodynamic and left ventricular pressure was measured by using Powerlab Data Acquisition System (4/25, AD Instrument). The femoral artery was cannulated for measurement of systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and heart rate with a pressure transducer (Statham p23Db, CA, USA) and a micromanometer- tipped catheter (Millar Instruments) was placed in the left ventricle via right carotid artery to record left ventricular function; left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), LV (dp/dt) max and LV (dp/dt) min. Data were analysed by using acquisition data system (AD Instruments Pvt. Ltd. with software LABCHART 8 pro software, Australia (19)).

**Biochemical Estimations in Serum**

The serum LDH activity and CK-MB activity were determined by kinetic methods (20, 21) using respective kits and UV spectrophotometer (Model-150-200, Hitachi, Japan). Serum Tn-T and TNF-α was measured by using rat specific Tn-T (Kinesis DX Ltd. USA) and TNF-α (Krishgen biosystem Ltd. India) ELISA kits on ELISA reader (Micro Scan MS5608A, Electronic Corporation of India, Hyderabad).

**Biochemical Estimations in Cardiac Tissue**

All animals were sacrificed at the end of the study, *i.e.* on the 15th day, the heart was immediately isolated. Tissue homogenates were prepared with 0.1 M tris-HCl buffer (pH 7.4) and supernatant of homogenates was employed to estimate reduced glutathione (GSH) (22), thiobarbituric acid reactive substance (TBARS) (23) and total protein (24) as described previously.

**Histopathological Evaluation**

The heart was fixed in 10% formalin solution for histopathological analysis. Formalin-fixed tissues (left ventricle) were embedded in paraffin, sectioned at 4 μm and stained with Masson’s trichrome. The sections were examined under light microscope, and the photomicrographs were taken. (25)

**Statistical analysis**

Statistical analysis was carried out using Graph Pad Prism 5.0 (Graph pad software; San Diego, CA). All data are expressed as mean ± standard error of mean (SEM). One-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparisons test. *P* < 0.05 was considered as significant.

**Results**

**Effect on Hemodynamic Parameters**

Treatment with CEL for 14 days significantly raised the SBP (*p* < 0.01) but not DBP, MAP and heart rate when compared with control. Furthermore, combination of BPS with CEL significantly (*p* < 0.01) reduced the SBP when compared with CEL (Table 1).

**Effect on left ventricular function**

Treatment with CEL also significantly increased (*p* < 0.01) the LVEDP and decreased (*p* < 0.05) the LV (dp/dt)_{max} and LV (dp/dt)_{min} as compared to control. Whereas, combination of BPS with CEL significantly decreased (*p* < 0.05) LVEDP and increased (*p* < 0.01) the LV (dp/dt)_{max} and LV (dp/dt)_{min} when compared to CEL treatment alone group (Table 2).

**Effect on heart weight/body weight (HW/BW) and left ventricle weight/body weight (LVW/BW) ratio**

Treatment with CEL significantly raised the HW/BW (*p* < 0.05) and LVW/BW (*p* < 0.01) as compared to control. Whereas, the combination of BPS with CEL significantly decreased the HW/BW and LVW/BW (*p* < 0.05) when compared to CEL treatment alone (Table 3).

**Effect on LDH and CK-MB**

Treatment with CEL significantly raised the
Table 1. Hemodynamic parameters in control (Group I), CEL per se (Group II), BPS (Group III), CEL + BPS (Group IV).

| Group | SBP (mmHg)      | DBP (mmHg)      | MAP (mmHg)      | HR (BPM)       |
|-------|-----------------|-----------------|-----------------|----------------|
| I     | 109.08 ± 2.35   | 83.22 ± 4.38    | 91.83 ± 3.53    | 322.06 ± 20.13 |
| II    | 125.78 ± 4.00   | 88.91 ± 2.61    | 101.19 ± 2.42   | 358.88 ± 16.58 |
| III   | 102.45 ± 4.99   | 79.59 ± 2.56    | 88.73 ± 5.55    | 310.39 ± 9.76  |
| IV    | 106.15 ± 2.56   | 74.73 ± 2.80    | 86.37 ± 3.91    | 308.23 ± 18.81 |

Values are expressed as mean ± SEM (n = 8) and analyzed by one-way ANOVA followed by Tukey-Kramer multiple comparison test. *p < 0.01 II v/s I and ** p < 0.01 IV v/s II. CEL: Celecoxib; BPS: Beraprost Sodium; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; HR: heart rate.

Table 2. Left ventricular function in control (Group I), CEL per se (Group II), BPS (Group III), CEL + BPS (Group IV).

| Group | LVSP (mmHg)     | LVEDP (mmHg)  | LV(dp/dt)max (mmHg/sec) | LV(dp/dt)min (mmHg/sec) |
|-------|-----------------|---------------|-------------------------|-------------------------|
| I     | 109.10 ± 2.23   | 3.27 ± 0.44   | 10930.71 ± 824.12       | -5892.81 ± 915.59       |
| II    | 111.53 ± 1.96   | 10.21 ± 0.59  | 6892.01 ± 407.67        | -3533.99 ± 314.10       |
| III   | 111.62 ± 3.07   | 6.28 ± 0.74   | 9970.62 ± 896.32        | -5017.58 ± 497.15       |
| IV    | 113.55 ± 1.54   | 4.49 ± 0.73   | 11324.63 ± 875.04       | -6710.85 ± 688.41       |

Values are expressed as mean ± SEM (n = 8) and analyzed by one-way ANOVA followed by Tukey-Kramer multiple comparison test. *p < 0.05 II v/s I, IV v/s II and **p < 0.01 II v/s I, IV v/s II. CEL: Celecoxib, BPS: Beraprost Sodium, LVSP: left ventricular systolic pressure, LVEDP: left ventricular end diastolic pressure, LV(dp/dt)max: maximum rate of rise of left ventricular function, LV(dp/dt)min: maximum rate of fall of left ventricular function.

Table 3. HW/BW and LVW/BW ratio in control (Group I), CEL per se (Group II), BPS (Group III), CEL + BPS (Group IV).

| Group | HW/BW     | LVW/BW     |
|-------|-----------|------------|
| I     | 2.49 ± 0.11| 1.10 ± 0.06|
| II    | 2.65 ± 0.13**| 1.45 ± 0.049**|
| III   | 2.64 ± 0.06| 1.01 ± 0.03|
| IV    | 2.60 ± 0.05*| 1.11 ± 0.06**|

Values are expressed as mean ± SEM (n = 8) and analyzed by one-way ANOVA followed by Tukey-Kramer multiple comparison test. *p < 0.05 IV v/s II and **p < 0.01 II v/s I, IV v/s II. CEL: Celecoxib, BPS: Beraprost Sodium, HW/BW: heart weight/body weight ratio, LVW/BW: left ventricle weight/body weight.

serum LDH (p < 0.05) and CK-MB (p < 0.01) as compared to control. Whereas, the combination of BPS with CEL significantly decreased (p < 0.05) the LDH and CK-MB level when compared to celecoxib treatment alone (Table 4).

**Effect on TBARS and GSH**

Treatment with CEL significantly raised the TBARS and GSH level (p < 0.01) as compared to control. Whereas, combination of BPS with CEL significantly (p < 0.05) decreased the TBARS and increased GSH level when compared to CEL treatment alone (Figure 1).

**Effect on Tn-T and TNF-α**

Treatment with CEL significantly (p < 0.001) raised the serum Tn-T and TNF-α level as compared to control. However, the combination of BPS with CEL significantly decreased (p < 0.05) the Troponin-T and TNF-α level when compared to celecoxib treatment alone (Figure 2).

**Effect on histopathology**

The masson’s trichrome staining of groups treated with 1% CMC (control) (A) and beraprost sodium (C) revealed normal myocardium with no
Beraprost sodium prevents celecoxib cardiotoxicity

Collagen deposition. Whereas group treated with celecoxib (B) showed a focal area of collagen deposition. The combination of beraprost sodium with celecoxib (D) revealed normal myocardium with very less collagen deposition. (Figure 3).

Discussion

Selective COX-2 inhibitors are widely used in the treatment of analgesic, anti-inflammatory, and antithrombotic (26), but its higher dose and long term use tightly associated with the myocardial infarction, atherosclerosis, heart failure and stroke (6). Thus, the present study was designed to investigate the effect of BPS on celecoxib induced cardiac toxicity in Wistar rats.

In our study, hemodynamic parameters were assessed for the better understanding of the celecoxib cardiotoxicity in cardiac biochemical and functional alterations. Selective COX-2 inhibitors, celecoxib showed slightly remarkable increased SBP (7). On the other hand, celecoxib failed to show any significant differences in heart rate, MAP, and DBP. In addition, it was also found that BPS treatment with celecoxib significantly demur the SBP level not heart rate, MAP and DBP when compared with the CEL alone group.

Hypertension is the dire consequence of cardiovascular diseases and strongly allied with the left ventricle hypertrophy, a state in which cardiac ventricle walls become thick along with increased pressure overload induced cardiac abnormality (27). Furthermore, In the present study, celecoxib treatment shot up the LVEDP, decrease LV (dP/dT)\text{max} and LV (dP/dT)\text{min} which is an important tool for the diagnosis of cardiovascular diseases. Whereas, concurrent

| Group  | LDH (IUL) | CK-MB (IUL) |
|--------|-----------|-------------|
| I      | 78.30 ± 4.07 | 41.65 ± 2.87 |
| II     | 107.47 ± 5.36* | 66.17 ± 4.93** |
| III    | 74.16 ± 4.5  | 43.47 ± 2.90 |
| IV     | 81.88 ± 4.32* | 46.10 ± 2.77* |

Values are expressed as mean ± SEM (n = 8) and analyzed by one-way ANOVA followed by Tukey-Kramer multiple comparison test. *p < 0.05 II v/s I, IV v/s II and **p < 0.01 II v/s I. CEL: Celecoxib; BPS: Beraprost Sodium; LDH: lactate dehydrogenase; CK-MB: creatine kinase-MB.

Figure 1. (A) Cardiac thio barbituric acid reactive substance (TBARS) level and (B) reduced glutathione (GSH) content activity in normal (Group I), CEL per se (Group II), BPS per se (Group III), and CEL + BPS (Group IV). Values are expressed as mean ± SEM (n = 8) and analyzed by one-way ANOVA followed by Tukey-Kramer multiple comparison test. *p < 0.05 II v/s I, IV v/s II. CEL: Celecoxib, BPS: Beraprost Sodium.
treatment of BPS with celecoxib significantly inhibit the increased LVEDP as compared to CEL treated groups.

In the present study, we found CEL treatment significantly increase the HW/BW and LVW/BW ratio, an important feature of cardiac hypertrophy development (28). Hypertrophy attributed to increased water content and oedema progression in intramuscular spaces, results in necrotic changes and inflammatory cells insult (29). However, it has been also found that BPS with celecoxib significantly reduced the HW/BW and LVW/BW.

Serum CK-MB and LDH is well known diagnostic enzymes marker of myocardial damage. Myocardial cells ruination due to insufficient oxygen supply or glucose, rupture cardiac membrane or make it permeable which leads to enzymes leakage and enters in to blood stream (30). In the current study, it was noticed that serum CK-MB and LDH elevation was observed in the COX-2 inhibitor, celecoxib treatment groups. This enhanced enzymes level in the serum advocate the myocardial membrane permeability deformities of celecoxib administration. Ueno et al. (18) reported that BPS defence of the myocardium against injury by suppressing enhanced CK-MB and LDH levels in occlusion/reperfusion injury animal model. Concurrent treatment of BPS with celecoxib attenuates the increased serum CK-MB and LDH.

GSH, a non enzymatic antioxidant is important in myocardial protection in response to free radical induced injury (28). Selective COX-2 inhibitors, celecoxib treated rats shows a significant change in the cardiac GSH level. However, treatment of BPS with celecoxib showed significant rise in cardiac GSH level. In line with our finding, Li et al. (14) also suggested that inhibition of ROS generation due to BPS could be associated with decreased GSH content in the cardiac tissue.

Lipid peroxidation involves oxidative deterioration of poly-unsaturated fatty acids associated with the abnormal membrane lipid bilayer arrangement and enzymes deactivation during myocardial ischemia (31). Increased TBARS is an important indicator of the ROS generation which might be associated with the oxidative tissue damage (32). These evidences were consistent with our findings. Elevated cardiac TBARS levels were also seen in celecoxib treated groups. BPS significantly decreased the cardiac TBARS levels in CEL that might be due to decreased lipid peroxides formation caused by oxidative stress which was supported by the previous studies (33).

Troponin T (Tn-T) considered as prognostic marker of drugs induced cardiac cell mishap in humans and animals (34). Enhanced troponin levels are important bacon for the increased
Beraprost sodium prevents celecoxib cardiotoxicity

Coronary disease, suboptimal coronary flow, diminished left ventricular systolic function and assessment of infarct size in myocardial infarction (35). It has been reported that loss of membrane integrity due to cardiac myocytes injury could be the main reason for the cardiac troponin release in the blood stream (36). In our study, we found significant increase in serum Tn-T levels in CEL induced cardiotoxicity as compared to control rats which is in agreement with the previous findings (37). However, treatment of BPS with celecoxib shows the remarkably decreased Tn-T levels when compared with CEL groups.

TNF-α, a pro-inflammatory cytokines and chemokines serves a key function in apoptosis, necrosis, and cells proliferation (38). In the cardiac tissue TNF-α shows cardiotoxic effect and slows down the contractile function, decreased β-adrenergic inotropic response and promotes pro-apoptotic pathways (39). In addition, previous studies supported that oxidative stress is a key factor for the exacerbation of pro-inflammatory cytokines (40). In the present study, we observed that celecoxib enhance the serum TNF-α level in rats. Previous animal study also found that celecoxib treatment increases the TNF-α concentration in the alcohol liver steatosis (41). It is noteworthy that oral treatment of BPS along with celecoxib had a significantly lower serum TNF-α concentration compared to CEL induced cardiotoxicity groups. Several lines of studies revealed that BPS decrease TNF-α level via its anti-inflammatory and anti-apoptotic potency in myocardial tissue (14). Histopathological findings celecoxib shows a focal area of collagen deposition. However, administration of BPS with celecoxib significantly reduces collagen deposition.
In conclusion, the present study confirmed that celecoxib produced cardiotoxicity induced by in rats as evident by the release of myocyte injury markers in serum. Further studies are needed to clarify the precise pathway for the celecoxib induced cardiotoxicity. Moreover, the current study provided experimental suggestion that BPS maintained the antioxidant levels by inhibiting ROS generation and inflammatory cells and also it improved the myocardial events against high dose celecoxib. This investigation could be a scientific support to understand the better therapeutic approach of BPS on cardioprotection against myocardial injury. Therefore, BPS may be a suitable adjunct for those patients already with celecoxib prescription.

Acknowledgements

The authors would like to acknowledge Dr. G.N. Qazi, Vice Chancellor, Dr. Asgar Ali, Dean Faculty of Pharmacy, Dr. Nilanjan Saha, Head, Department of Pharmacology for providing necessary facilities to carry out the study. We also thankful to Aurobindo Pharma Ltd., India to offer celecoxib as a gift sample and lastly to the University Grant Commission (UGC), New Delhi, India for providing JRF to the first author.

References

(1) Anwar A, Anwar IU and Delafontaine P. Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. Trends Cardiovasc. Med. (2015) 25: 726-35.
(2) Brock TG, McNish RW and Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J. Biol. Chem. (1999) 274; 11660-6.
(3) Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ and Hochberg MC. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. (2000) 343; 1520-8.
(4) Ghosh R, Alajbegovic A and Gomes AV. NSAIDs and cardiovascular diseases: Role of reactive oxygen species. Oxid. Med. Cell. Longev. (2015) 2015: 536-962.
(5) Caldwell B, Aldington S, Weatherall M, Shirtcliffe P and Beasley R. Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J. R. Soc. Med. (2006) 99: 132-40.
(6) Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. (2005) 352: 1071-80.
(7) Muscarà MN, Vergnolle N, Louren F, Triggie CR, Elliott SN, Asfaha S and Wallace JL. Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br. J. Pharmacol. (2000) 129: 1423-30.
(8) Zaitone SA, Moustafa YM, Mosaad SM and El-Orabi NF. Effect of evening primrose oil and omega-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats. J. Cardiovasc. Pharmacol. (2011) 58: 72-9.
(9) Ohno K, Nagase H, Matsunami K, Nishiyama H and Nishio S. Stereoselective synthesis of 5, 6, 7-trinor-4, 8-inter-m-phenylene-PGI2 derivatives and their inhibitory activities to human platelet aggregation. Adv. Prostaglandin Thromboxane Leukot. Res. (1984) 15: 279-81.
(10) Akiba T, Miyazaki M and Toda N. Vasodilator actions of TRK-100, a new prostaglandin I2 analogue. Br. J. Pharmacol. (1986) 89: 703-11.
(11) Nishio S, Matsuura H, Kanai N, Fukatsu Y, Hirano T, Nishikawa N, Kameoka K and Umetu T. The in-vitro and ex-vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn. J. Pharmacol. (1988) 47: 1-10.
(12) Umetu T, Murata T, Tanaka Y, Osada E and Nishio S. Antithrombotic effect of TRK-100, a novel, stable PG1 analogue. Jpn. J. Pharmacol. (1987) 43: 81-90.
(13) Origasa H, Ikeda Y, Shimada K and Shigematsu H. Oral beraprost sodium as a prostaglandin I, analogue for vascular events in patients with peripheral arterial disease: Meta-analysis of two placebo-controlled randomized trials. Jpn. J. Pharmacoepidemiol. (2004) 9: 45-51.
(14) Li J, Peng L, Du H, Wang Y, Lu B, Xu Y, Ye X and Shao J. The protective effect of beraprost sodium on diabetic cardiomyopathy through the inhibition of the p38 MAPK signaling pathway in high-fat-induced SD rats. Int. J. Endocrinol. (2014) 901437.
(15) Vicil S and Erdogan S. Beraprost sodium, a prostacyclin (PGi) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cells. Turk. J. Med. Sci. (2015) 45: 284-90.
(16) Lefer AM, Ongtree ML, Smith JB, Silver MJ, Nicolaou KC, Barnett WE and Gasic GP. Prostacyclin: A potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science (1978) 200: 52-4.
(17) Ashkavand Z, Malekinejad H, Amniatollah A, Rezaei-Golmisheh A and Vishwanath BS. Silimarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats. Phytomedicine (2012) 19: 1200-5.
(18) Ueno Y, Koike H, Annoh S and Nishio S. Effects of beraprost sodium, a prostacyclin analogue, on tail flick response in two models of diabetic-neuropathy in rats.
Beraprost sodium prevents celecoxib cardiotoxicity and its mechanism. *Life Sci.* (1996) 59: 105-10.

(19) Parveen A, Babbar R, Agarwal S, Kotwani A and Fahim M. Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats. *Cardiovasc. Toxicol.* (2011) 11: 48-57.

(20) Bergmeyer HU. *Method of enzymatic analysis*, 2nd ed. Vevlag Chemie. Weinheim: Academic Press, London (1965) 574-9.

(21) Rosalki SB. An improved procedure for serum creatine phosphokinase determination. *J. Lab. Clin. Med.* (1967) 69: 696-705.

(22) Sedlak J and Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. *Anal. Biochem.* (1968) 25: 192-205.

(23) Ohkawa H, Ohishi N and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal. Biochem.* (1979) 95: 351-8.

(24) Lowry OH, Rosebrough NJ, Farr AL and Randall RJ. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* (1951) 193: 265-75.

(25) Carson FL and Hladik C. *Histotechnology: A Self-Instructional Text*. 1st ed. ASCP (1990) 142-3.

(26) Kainoh M, Nishio S and Nakadate T. Cytoprotective action of beraprost sodium against peroxide-induced damage in vascular endothelial cells. *Pharmacology* (1992) 45: 61-70.

(27) Bertsch T, Bleuel H, Aufenanger J and Rebel W. Comparison of cardiac troponin T and cardiac troponin I concentrations in peripheral blood during orciprenaline induced tachycardia in rats. *Exp. Toxicol. Pathol.* (1997) 49: 467-8.

(28) Rao SV, Ohman EM, Granger CB, Armstrong PW, Gibler WB, Christenson RH, Hasselblad V, Stebbins A, McNulty S and Newby LK. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. *Am. J. Cardiovasc. Pathol.* (2003) 91: 936-40.

(29) Wells SM and Sleeper M. Cardiac troponins. *J. Vet. Emerg. Crit. Care* (2008) 18: 235-45.

(30) Zhang J, Knapton A, Lipshultz SE, Weaver JL and Herman EH. Isoproterenol-induced cardiotoxicity in sprague-dawley rats: Correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. *Toxicol. Pathol.* (2008) 36: 277-8.

(31) MacEwan DJ. TNF receptor subtype signalling: Differences and cellular consequences. *Cell. Signal.* (2002) 14: 477-92.

(32) Krown KA, Page MT, Nguyen C, Zechnier D, Gutierrez V, Comstock KL, Glembocki CC, Quintana P and Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. *J. Clin. Invest.* (1996) 98: 2854.

(33) Mak S and Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. *Chest* (2001) 120: 2035-46.

(34) Bykov I, Palmen M, Rainsford K and Lindros K. Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats. *Inflammopharmacol* (2006) 14: 36-41.

This article is available online at http://www.ijpr.ir